We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 145

New EU competition rules on technology transfer agreements
  • Norton Rose Fulbright LLP
  • European Union
  • April 4 2014

The European Commission has recently announced its adoption of a revised Technology Transfer Block Exemption Regulation and new accompanying


Social media: did you know?
  • Norton Rose Fulbright LLP
  • Global
  • March 20 2014

How many of us actually read social media terms of use? Be wary: you allow public information to be accessible over public search engines. When you


Federal Court rejects all allegations of invalidity and grants prohibition order to Pfizer
  • Norton Rose Fulbright Canada LLP
  • Canada
  • December 18 2009

On December 18, 2009, the Federal Court granted an application by Pfizer Canada Inc. and Pharmacia Aktieblolag (“Pfizer et al”) for an order prohibiting the Minister of Health from issuing a notice of compliance to Pharmascience Inc. (“PMS”) in respect of a generic version of XALATAN until the expiry of Canadian Patent No. 1,339,132 (“132 patent”


USPTO announces pilot program to accelerate examination of patent applications for green technologies
  • Norton Rose Fulbright Canada LLP
  • USA
  • December 15 2009

On December 7, 2009, the United States Patent and Trademark Office (USPTO) announced the "Pilot Program for Green Technologies Including Greenhouse Gas Reduction"


Federal Court upholds Commissioner’s decision to refuse to grant a patent on the ground of obviousness double patenting
  • Norton Rose Fulbright Canada LLP
  • Canada
  • December 21 2009

On December 8, 2009, the Federal Court dismissed an appeal by Bayer of a decision of the Commissioner of Patents refusing to grant a patent for Patent Application No. 508,336 (the '336 Application) on the basis of obviousness double patenting


A standard year for the European Commission
  • Norton Rose Fulbright LLP
  • European Union
  • February 17 2010

At the end of 2009, the European Commission closed two long-running investigations into misuse of market power afforded to companies whose patented technology had been incorporated into industry standards: the Rambus case and the Qualcomm case


Supreme Court of Canada grants leave to appeal in a case concerning the jurisdiction of the PMPRB
  • Norton Rose Fulbright Canada LLP
  • Canada
  • April 22 2010

On April 22, 2010, the Supreme Court of Canada granted Celgene Corporation’s application for leave to appeal the decision of a majority of the Federal Court of Appeal (“FCA”) regarding the jurisdiction of the PMPRB (the “Board”


Repercussions of the Amazon decision on BIO-IT patents in Canada
  • Norton Rose Fulbright Canada LLP
  • Canada
  • September 10 2009

The Patent Appeal Board (C.D. 1290) recently rejected the Amazon "One-Click" patent application (Canadian application No. 2,246,933) based on non-statutory subject matter


Bio-IT - the next generation of patents
  • Norton Rose Fulbright Canada LLP
  • Canada
  • May 6 2009

The pharmaceutical, biotech, hardware, and software industries are exploring new ways to share complex biomedical data and to accelerate the pace of discovery in the area of life sciences


Google’s AdWords should not be held to infringe trade marks, says Advocate General
  • Norton Rose Fulbright LLP
  • European Union
  • September 30 2009

In a blow for brand owners, the legal advisor to the European Court of Justice (ECJ) has stated that the Google AdWords system does not infringe third party trade mark rights